Although most pulmonary cytologic specimens obtained by either exfoliation or fine needle aspirates can be reliably and accurately diagnosed based on pure morphologic criteria alone, a small proportion of cases require ancillary studies for either refining a diagnosis, for resolving a differential diagnosis or increasingly, for predictive purposes in primary lung carcinomas. This article aims to provide practical guidance on the use of common ancillary studies in pulmonary cytologic specimens. Cancer Cytopathol 2018;126:599-614.
INTRODUCTION
Although most cytologic specimens obtained by either exfoliation or fine needle aspirate (FNA) can be reliably and accurately diagnosed based on morphological criteria alone, a small proportion of cases require ancillary studies for either refining a diagnosis (eg, determining the etiology of granulomatous inflammation), for resolving a differential diagnosis (eg, subtyping of poorly differentiated carcinomas) or, increasingly, for predictive purposes in primary lung carcinomas. The goal of this article is to provide practical guidance for the use of common ancillary studies in pulmonary cytologic specimens; a summary of the overall simplified approach is provided in Fig 1. 
DETECTION OF INFECTIOUS AGENTS
The most common application of cytology in benign pulmonary lesions is for the detection of lung infections, especially for immunocompromised patients including HIV/AIDS patients, patients with known malignancies, and transplant patients. To increase the accuracy and sensitivity of the cytology specimens, typically bronchoalveolar lavages (BAL) or bronchial washings but occasionally induced sputa or more rarely lung FNAs, a multimodal assessment for infectious organisms, including cultures, various pathogen specific histochemical stains (eg, Ziehl-Nielsen stain for mycobacterium), immunohistochemistry, and molecular detection, is recommended in addition to obtention of clinical history and correlation with corresponding tissue biopsies. 1 In such specimens from immunosuppressed patients, one must look most particularly for fungi (including Pneumocystis jiroveci) and for viral changes.
When assessing lung cytology specimens for fungal infections, one must keep in mind that sputum samples, bronchial washes, and even BAL can be contaminated with oral Candida; this possibility should be mentioned in the report, particularly if the samples contain many benign squamous cells, which are indicative
Cancer Cytopathology August 2018 of contamination. However, cytopathologic detection of a fungal organism in a sterile site with associated tissue damage is considered proven invasive fungal disease; such an example would be an FNA of a lung nodule or cavity. 2, 3 The morphology of the organism, which is often best appreciated with Grocott/Gomori's methenamine silver (GMS) stain, can often suggest the species of the organism. (A detailed description of the morphology of the various fungi is beyond the scope of this article.) In practice, BAL is a valuable tool for diagnosing invasive pulmonary aspergillosis in immunocompromised patients. Aspergillus hyphae are usually easy to recognize (septate hyphae, acute angle branching) either on cytology or cell block preparation. The main differential diagnosis is mucormycosis (nonseptate, wider hyphae with 90° angle branching), but this species is much less frequent. Microbiologic biomarker testing (eg, galactomannan) and molecular techniques can help determine the specific species and antibiotic sensitivity.
Pneumocystis jirovecii, now considered a fungus, can be detected in BAL specimens, bronchial washings, and induced sputa. Infection rates are decreasing given widespread use of prophylactic therapy. The organisms are not visible on Papanicolaou staining, but suspicion should be raised if foamy alveolar casts of proteinaceous material are seen ( Fig. 2A) . Confirmation of the diagnosis can be achieved with the use of GMS stain (in smears or cell blocks) which highlights the cup-shaped cysts (5-7 μm in diameter) and the central dark zone (Fig. 2B) . Detection of the organism can also be performed with immunofluorescence, polymerase chain reaction (PCR) or immunohistochemistry. 4 Of note, GMS stain also helps distinguishing Pneumocystis jiroveci infection from alveolar proteinosis because the eosinophilic debris of the latter, which may resemble the proteinaceous exudates seen in Pneumocystis infections, are negative on GMS stain, being devoid of microorganisms. Viral infections can often be detected and accurately diagnosed in cytology specimens by examining Overall simplified approach to the use of ancillary studies in pulmonary cytologic specimens (for malignancies, it applies to lung primaries only [ie, it excludes nonpulmonary primary malignancies]). Abbreviations: AdenoCA, adenocarcinoma; CA, carcinoma; FNA, fine needle aspirate; GMS, Grocott/Gomori's methenamine silver; IHC, immunohistochemistry; NET, neuroendocrine tumor; NOS, not otherwise specified; NSCLC, non-small cell lung carcinoma; ZN, Ziehl-Nielsen stain.
Cancer Cytopathology August 2018 nuclear features, presence of inclusions, and/or cytoplasmic changes. Whereas herpes simplex virus-infected cells typically display multinucleation, nuclear molding, and margination of chromatin (the so-called "3-M" features), cytomegalovirus-infected cells exhibit cytomegaly and often have basophilic nuclear and cytoplasmic inclusions (Fig. 3) . When in doubt as to the exact nature of the inclusions and the virus, immunocytochemical staining of the sample (mostly on cell blocks), in addition to other modalities, effectively make confirmation of positive cases possible (Fig. 3, inset) . When there is insufficient material for cell block preparation, immunocytochemistry can also be successfully performed on additional slides (cytospins or liquid-based slides) from leftover material of the sample; the interpretation of immunostains on slides tends, however, to be more challenging than on cell blocks as there is often more background nonspecific staining.
Granulomatous inflammation (necrotizing or nonnecrotizing) is another context within which GMS and Ziehl-Nielsen stains (or auramine immunofluorescence stain) should be ordered for fungi and mycobacteria, respectively. If positive, the identification of an infectious cause for the granulomatous inflammation will guide proper management in a timely manner, as cultures may take significantly longer, especially for mycobacteria.
Finally, whenever lung or mediastinal lymph node FNAs consist entirely of necrotic debris, special stains for fungi and mycobacteria should also be performed because, if positive, they can change a nondiagnostic specimen into a diagnostic one.
ANCILLARY STUDIES IN NON-SMALL CELL LUNG CARCINOMA
Once a pulmonary cytologic specimen (either exfoliative or FNA) is deemed malignant and of epithelial derivation (ie, carcinoma), the next tasks are to 1) determine whether the carcinoma is a small cell carcinoma (SCC) or a non-small cell lung carcinoma (NSCLC), and 2) if NSCLC, determine whether it is a squamous cell carcinoma versus an adenocarcinoma ( Fig. 1 and Table 1 ). This approach, as detailed below, only applies to lung primaries and not to metastatic carcinomas from other sites, based on correlation of pathologic data with clinical and radiologic findings (as discussed in the "Ancillary Studies for Metastases" section below). 
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Accurate subtyping of NSCLC is now crucial in cytologic specimens in the current era of targeted therapy. If the NSCLC is well-differentiated and exhibits either clear-cut/unequivocal squamous or glandular differentiation based on the cytologic features alone, immunocytochemistry does not have to be performed, and a definite diagnosis of squamous cell carcinoma or adenocarcinoma can be reported (Fig. 4) . [5] [6] [7] However, immunocytochemical tests must be ordered whenever an NSCLC is not well-differentiated or shows any equivocal cytological features and for which a cell block is available to attain a more specific subtype of NSCLC; indeed, the diagnosis "NSCLC, not otherwise specified (NOS)" should be kept to a minimum. 5, [8] [9] [10] Because it is important to conserve as much material as possible for subsequent molecular testing (see Cancer Cytopathology August 2018
also "Molecular and Predictive Testing in Lung Cancer" below), it is recommended that the number of hematoxylin and eosin-stained levels be minimized, cell block trimming be reduced, and redundant immunohistochemistry be avoided. 1, 5, [8] [9] [10] Although mucin stain (such as mucicarmine) is an acceptable ancillary stain, it is best to refrain from using it because it is not sensitive for adenocarcinoma; instead, it is recommended that thyroid transcription Factor 1 (TTF1) or napsin A be used for the determination of glandular differentiation ( Fig. 5 ). Although both TTF1 and napsin A exhibit excellent (albeit imperfect) sensitivity for adenocarcinoma, the advantage of TTF1 is that it confirms a pulmonary origin, provided thyroid carcinoma is not in the differential diagnosis. In addition, it should be noted that TTF1 is also frequently (but not always) positive in many neuroendocrine tumors of the lung as well as in high-grade neuroendocrine tumors of extrapulmonary origin (see also "Pulmonary Neuroendocrine Tumors and Their Differential Diagnosis" and "Ancillary Studies for Metastases" below). For squamous differentiation, immunostaining for p40 is recommended; other acceptable alternatives include p63 or cytokeratins 5/6 ( Fig. 6 ).
Combinations of immunocytochemical markers, typically combining a nuclear staining antibody with a cytoplasmic staining antibody (eg, TTF1 and napsin A; P40 and CK5/6) can also be used to save material for molecular studies. 8, [11] [12] [13] [14] [15] Finally, some institutions can also opt to perform ancillary studies on all NSCLC, even when well-differentiated; however, such an approach is not desirable nor necessary in cost-conscious settings.
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Of note, the phrasing of the diagnosis in the cytology report (as is for histologic reports) depends on the use (or not) of ancillary studies (Fig. 1) . If the diagnosis can be reached without any ancillary studies, the wording "adenocarcinoma" or "squamous cell carcinoma" should be used. If ancillary studies are required to reach a diagnosis, the phrasings "NSCLC, favor adenocarcinoma" or "NSCLC, favour squamous cell carcinoma" are recommended; and if the ancillary studies are noncontributory (ie, negative), the diagnosis should be "NSCLC, not otherwise specified." 8, 16 Of note, if a tumor is positive for TTF1 or for napsin A, focal p40 positivity does not change the diagnosis and the tumor should be considered an adenocarcinoma, unless there are 2 clear-cut/distinct cell populations, each staining differentially; in such situation, a diagnosis of adenosquamous carcinoma should be considered. 8 Some immunostains are not very useful for subtyping NSCLC and their use is therefore discouraged. For example, cytokeratin 7 can be positive in all lung carcinomas, including SCC, and although it stains most of the pulmonary adenocarcinomas, it is also positive in many poorly differentiated squamous cell carcinomas. Likewise, although 34βE12 stains most squamous cell carcinomas, it is also positive in many poorly differentiated adenocarcinomas.
Finally, it should be noted that invasive mucinous adenocarcinomas in pulmonary specimens, even when primary in the lung, tend to stain differently from the "usual" immunophenotype of primary lung adenocarcinomas (see also "Ancillary Studies for Metastases").
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Molecular and Predictive Testing in Lung Cancer
A surge of effective treatments for NSCLC, including small molecule tyrosine kinase inhibitors (TKIs) and immunotherapies, have been developed and approved in the last decade. TKI treatment, through blocking of dominant oncogenes, effectively halts carcinoma survival. Predictive biomarker testing of these driver oncogenes, which includes both molecular and immunohistochemistry testing, now plays a pivotal role in the standard of patient care and should at least be performed for all patients having stage III and IV nonsquamous NSCLC; at the discretion of individual institutions, such testing may also be performed for patients presenting with lower stages of disease. Importantly, approximately 20% of biopsies are insufficient for biomarker testing, requiring additional material for testing. This leads to additional invasive procedures and associated risks, delays in treatment, and additional cost for the health system. Increased turnaround time can have a significant adverse effect on wait times and even survival in lung cancer patients. 17 Reflex testing on all small biopsies/cytology specimens, Cancer Cytopathology August 2018 on the assumption that most patients are of advanced stage, can effectively decrease turnaround time (up to 20% in our experience) and the wait time to targeted therapy in patients with advanced NSCLC.
Driver oncogene mutations include small point mutations, insertions or deletions, or gene fusions through translocations, and biomarker testing relies on nucleic acid detection-based techniques such as sequencing, PCR, and fluorescence in situ hybridization (FISH) or by immunohistochemistry. As such, the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association of Molecular Pathology provided guidelines in 2013 to set standards for the molecular analysis of lung cancers. 18 The guidelines have been revised recently, 19 and the reader is encouraged to become familiar with them, especially as cytology specimens are increasingly used for treatment decisions. Many of the patients are not eligible for tumor resection due to late stage presentation, and biomarker testing often depends on limited samples provided by cytology or small tissue biopsies. Moreover, diagnosis is based on only the cytology specimens in up to half of patients. 20 It is recommended that any cytology samples, blocks, or smears, with adequate cellularity and preservation, may be tested. 19 At a minimum, it is strongly recommended that epidermal growth factor receptor (EGFR), anaplastic lymphoma receptor tyrosine kinase (ALK ), and ROS proto-oncogene 1 receptor tyrosine kinase (ROS1) need to be tested on all lung cancer patients, and other genes such as v-Raf murine sarcoma viral oncogene homolog B (BRAF), rearranged during transfection (RET ), Erb-b2 receptor tyrosine kinase 2 (ERBB2/HER2), KRAS proto-oncogene GTPase (KRAS), and MET proto-oncogene receptor tyrosine kinase (MET ) are appropriately tested as part of initial larger panels or when EGFR, ALK, and ROS1 are negative. 19 Biomarker testing in lung cancer is based on detection of protein expression by immunohistochemistry, translocations by FISH, and mutation testing in extracted nucleic acids by molecular techniques (eg, PCR and sequencing technologies). Most cytological specimens are adequate for molecular analysis (eg, EGFR), immunohistochemistry (for ALK or ROS1 protein), FISH (ALK or ROS1) or in larger panels with targeted next-generation sequencing (NGS). 20 However, the yield and performance of these tests depends on 2 main factors: 1) the number of tumor cells (usually >100) and 2) the percentage of tumor cells (key factor for reducing false-negative in molecular studies where the tumoral DNA is mixed with normal DNA). The limit of detection depends on the sensitivity of the analysis used; respective limits of detection are 10% to 20% for Sanger sequencing, 1% to 8% for NGS, and 1% to 5% for real-time PCR. 21 Several limitations in cytology specimens can lead to false-negative results. The first pass in an FNA is often used for diagnostic smears, whereas subsequent passes often contain fewer tumor cells and more blood. Recent studies have shown that scraping cells from stained FNA smears or touch preparations can yield sufficient DNA for targeted NGS; results have been comparable to those of small biopsies and cell blocks if the cellularity was over 20%. 20 It is the role of the laboratory to perform appropriate validation studies of these distinct samples.
Although any cytology specimen can be used, the pathologist must carefully choose the best material available for molecular testing (biopsies, cell block, and diagnostic smears). Lung adenocarcinomas have EGFR mutations in 10% to 20% of cases; these mutations can be treated effectively with TKIs. Most mutations are found in exons 18-21 of the EGFR gene. Most sensitizing mutations are point mutations in exon 21 and in-frame deletions in exon 19. The T790M mutation is well known for acquired resistance in EGFR TKI-treated tumors. It is strongly recommended that patients who experience treatment failure with TKIs are tested for this mutation with an assay capable of detecting the mutation in as little as 5% of viable cells. 19 This can be performed through a limited biopsy (cytology or core biopsy), which need only be assessed for tumor cellularity before being processed for detection of T790M. Of note, although there are commercially available mutation-specific antibodies available for the 2 most common EGFR mutations, these are not recommended for selection of patients for TKI therapy.
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The oncogenic activation of the ALK gene occurs by gene rearrangement with a partner gene (eg, EML4-ALK, NMP-ALK ). The ALK gene is altered in 1% to 5% of adenocarcinomas. This leads to overexpression of the protein that can also be inhibited by specific TKIs (crizotinib, approved in 2011 by the US Food and Drug Administration). It can be detected by immunohistochemistry, which is highly sensitive and specific, on small Cancer Cytopathology August 2018 biopsies or cytology cell blocks. 23 Immunohistochemistry is now considered an equivalent alternative to FISH for ALK testing. 19 More recently, ROS1 has been added to the list of actionable targets in adenocarcinomas. ROS1 translocations are rare events in adenocarcinomas (approximately 1%), but ROS1 mutation testing is strongly recommended. 19 It is currently recommended that ROS1 immunohistochemistry be performed for screening; however, positive immunohistochemistry needs to be confirmed by molecular or cytogenetic testing. 19, 24 Many other driver mutations have been found for NSCLC, and inhibitors for these are being investigated. Routine stand-alone testing is not recommended outside of clinical trials, but it is suggested as part of larger testing panels with multiplexed genetic sequencing panels over multiple single-gene tests. 19 These include BRAF, RET, ERBB2 (HER2), KRAS, and MET, but the list will certainly expand (eg, MEK1, NTRK1, PIK3CA, NRAS, etc) as testing guidelines are revised. Notably, the latest National Comprehensive Cancer Network guidelines recommend including BRAF profiling with initial rounds of testing. 25 Immunotherapy, which leads to activation of immune-cell mediated killing of cancer cells, has rapidly become the standard of care for advanced stage lung cancers. One example targets the interaction of the programmed cell death 1 (PD-1) receptor with its ligand PD-L1. At present, several antibody-based treatments have been approved to target this interaction, either by binding to PD-1 or to PD-L1. As such, detection of PD-L1 by immunohistochemistry in biopsy specimens or resections has predictive value, and testing is strongly recommended for both adenocarcinoma and squamous cell carcinoma. 25 However, several pre-analytic and analytic issues affect PD-L1 immunohistochemistry. 26, 27 Different commercially available anti-PD-L1 antibody clones are available for testing, and these have proven to not be equivalent. 28 Testing is also performed on different immunohistochemistry platforms using different reagents and assay conditions. Interpretation of the test is difficult and requires specific training, and depending on which assay is used, positive PD-L1 staining is assessed in either the tumor cells or tumor cells and tumor-infiltrating inflammatory cells. Results are reported as a tumor proportion score (TPS) or tumor cell expression and immune cell expression when needed.
Clinical TPS thresholds are agent-specific and vary with treatment phases (eg, first-line or second-line treatment). Resected tumors have also been shown to exhibit heterogeneous staining, leading to false-negative results in small specimens (biopsies or cytology). Although original clinical and technical validation for the PD-L1 assays in clinical trials were performed on biopsy or resection specimens, several recent studies have shown that cytology blocks are at least technically comparable to biopsy specimens. 26, [29] [30] [31] Internal validation of the assays is crucial to avoid false-positive and false-negative tests.
Given the growing multitude of tests now required, both diagnostic and predictive, it is critical that a well-established protocol is set in place, especially with limited biopsy material. Ideally, these would allow for diagnostic immunohistochemistry and sufficient tissue for all required biomarker testing, while at the same time avoiding redundancy and wastage (Fig. 7) . In addition, adoption of multiplex testing, such as NGS sequencing, is crucial to achieve maximal results.
PULMONARY NEUROENDOCRINE TUMORS AND THEIR DIFFERENTIAL DIAGNOSIS
Primary neuroendocrine tumors (NET) of the lung include a range that consists of low-grade typical carcinoids (TCs), intermediate-grade atypical carcinoids (ACs), and high-grade neuroendocrine carcinomas, which include SCC and large cell neuroendocrine carcinoma (LCNEC). 8 From a practical standpoint, it is usually easy to recognize TCs and SCC in cytologic specimens. Differentiating LCNEC from SCC, ACs from TCs, and ACs from SCC may be problematic and may require a comparison with tissue biopsy specimens. 8, 32, 33 Mitotic rate, a feature that separates TCs, ACs, and LCNEC in histologic material is not specifically standardized for cytologic material; therefore, accurate assessment of this Cancer Cytopathology August 2018 feature can rarely be done on cytology samples, even in cell blocks. 33 Consequently, it is best to recommend surgical biopsy or excision of the tumor for definitive histologic diagnosis when the cytologic diagnosis is doubtful. Cytologically, TCs are composed of loosely cohesive clusters and uniform isolated cells that are small with round, oval, or spindled nuclei, coarsely granular chromatin pattern, and ample cytoplasm. Cell block sections may show nests, rosettes, and trabecula. 33 ACs show cytologic features similar to TCs with more mitotic activity and/or focal necrosis. 8, 32, 33 Cytology samples from SCC tend to be cellular with loosely cohesive sheets and single round, oval, or spindled cells with high nuclear-to-cytoplasmic ratios and finely granular chromatin pattern without nucleoli. Crush artifact with smearing of nuclei, necrosis, and apoptotic bodies may be seen. 8, 32, 33 Cytological features of LCNEC show similarity to SCC, but LCNEC tends to show nucleoli and abundant cytoplasm hinting a NSCLC. 8, 33 When encountering a possible NET, immunohistochemistry is helpful to confirm epithelial origin and neuroendocrine differentiation. Markers used for neuroendocrine differentiation include chromogranin, synaptophysin (cytoplasmic staining pattern), and CD56/ NCAM (membranous staining pattern). CD56 is considered the most sensitive, but is a less specific marker of neuroendocrine differentiation. 8, 14 Of note, the staining intensity of CD56 does not diminish with crushing artifact or decalcification, which can be useful when dealing with such circumstances. 34 Table 2 summarizes the immunocytochemical features of the pulmonary NETs. Carcinoids (TCs and ACs) tend to be strongly positive for CD56, synaptophysin, and chromogranin. Reactivity for pancytokeratin is common in carcinoids, but up to 20% to 25% can be negative. Most are negative for TTF1, but some peripheral ones may show expression. 32 ( Fig. 8 ) Carcinoids lack expression of CK5/6, p40
and napsin A, but may show focal expression of p63 in a small proportion of cases. 35, 36 Small cell carcinoma is positive for pancytokeratin and CAM5.2 with dot-like paranuclear or diffuse cytoplasmic staining pattern, but negative for high molecular weight keratins. Small cell carcinoma can show diffuse and strong staining for synaptophysin and CD56 but tends to show focal and weak staining with chromogranin; in fact, if staining for chromogranin is strong, consideration should be given to the possibility of an AC, because it is unusual for SCC to exhibit strong positivity for chromogranin. Small cell carcinoma is positive for TTF1, but negative for napsin A and p40 and may show focal expression of p63. It also lacks diffuse staining for CK5/6. 8, 14, 35, 36 The proliferation index is >50% and is approaching 100% 8, 34 ( Fig. 9 ).
LCNEC is an NSCLC showing neuroendocrine features; unlike SCC, it is typically located peripherally in the lung and rarely shows bulky enlargement of hilar lymph nodes. A diagnosis of LCNEC requires confirmation of neuroendocrine differentiation by markers. 8 Using NGS, it was found that at a molecular level, LCNECs are heterogeneous and comprise small cell-like, non-small cell/adenocarcinoma-like, and carcinoid-like genomic subsets. 37 LCNEC is positive for CD56, chromogranin A, and synaptophysin in decreasing order of frequency. It is positive for pancytokeratin, low molecular weight keratin, and CK7. 8 Approximately 50% are positive for TTF1. Some may show positivity for p63. 8, 14 Although napsin A expression is not seen in TCs, ACs, or SCC, it can be expressed in a subset of LCNEC at a lower level than adenocarcinoma; it was shown that these LCNECs harboured mutations typical of lung adenocarcinoma. 38 Of note, 5% to 10% of SCCs and LCNECs may lack expression of all 3 neuroendocrine markers. 34 The proliferation index is high (40% to 80%), and necrosis may be present. 8, 33 It is more important to differentiate SCC and LCNEC from low/intermediate grade NETs because of management differences and prognosis. Although the Ki-67 labeling index (LI) is not used to diagnose/ Cancer Cytopathology August 2018 differentiate lung NETs, it is helpful in assessing the proliferative rate and to further characterize these neoplasms on small samples. 33, 34, 39 One study on cytology samples (smears) of NET of lung, pancreas, and gastrointestinal tract, excluding LCNEC, showed that the Ki-67 LI was <25% versus >50% in low grade versus high-grade neoplasms when they were divided into 2 categories. 40 In another, the Ki-67 LI was calculated on cell block sections; TCs showed Ki-67 LI ranging from 1% to 5%, ACs from 3% to 10%, SCC >70% (median of 90%), and LCNEC 60%. 34 In a recent study comparing the Ki-67 LI on biopsy and corresponding resection samples and using different counting methods, a cutoff value of 20% optimally discriminated between TCs/ACs and LCNEC/ SCC regardless of the counting method. 41 NETs may be confused with hematolymphoid proliferations. Lymphoid cells have less cytoplasm compared with carcinoid tumors and generally do not form clusters. Use of lymphoid immunohistochemical markers as well as keratins and neuroendocrine markers may be helpful in ruling out a lymphoid process.
Differential diagnosis of SCC includes other primary NSCLC, especially basaloid squamous cell carcinoma, and other tumors such as Merkel cell carcinoma, and Ewing family tumors (EWFTs). Immunohistochemistry is helpful in differentiating these tumors. 8, 15, 42 Basaloid squamous cell carcinoma shows strong immunoreactivity for p40, p63, and/or high molecular weight keratins, but generally not for TTF1 and neuroendocrine markers. Merkel cell carcinoma, a NET, is immunoreactive for CK20, but not for CK7 or TTF1. EWFTs generally lack keratin expression, show diffuse membranous positivity with CD99, and a lower KI-67 LI. Also, FISH for the Ewing sarcoma breakpoint region 1 (EWSR1) gene helps to confirm the diagnosis.
ANCILLARY STUDIES FOR METASTASES
The lung is one of the most common sites of distant metastases, and metastatic carcinomas are frequently encountered in lung cytology specimens. Because the treatment differs significantly between primary and metastatic carcinomas, and with both presenting a wide morphological spectrum, incorporating clinical, radiological, and immunohistochemical findings is essential in this distinction. In general, a known history of nonpulmonary malignancy, an unusual morphology, or unusual results in the initial immunopanel such as TTF1 and napsin A negativity in an adenocarcinoma, should all prompt additional workup to exclude metastases. 43 Table 3 includes the best antibodies to use in differentiating various carcinoma types, and Figs 10 and 11 show examples of metastatic colorectal a denocarcinoma and renal cell carcinoma, respectively.
There are a several caveats that cytopathologists should be aware of when interpreting the immunoresults of different markers:
• Pulmonary adenocarcinoma, of the enteric/mucinous type, can be positive for CK20 and CDX2 and negative for TTF1 and napsin A. In this setting, SATB2 and villin are more specific for metastatic colorectal adenocarcinoma. 44, 45 • Clear cell renal cell carcinoma can be positive for napsin A. In addition, papillary renal cell carcinoma is typically positive for napsin A and CK7. 46, 47 • Metastatic urothelial carcinoma can show squamous differentiation simulating primary lung squamous cell carcinoma at the morphological and immunocytochemical levels, including positivity for P40, CK5/6, and GATA3. CK7, CK20, and uroplakin 2 are more useful markers in this setting, although the distinction may be extremely challenging in individual cases. The same difficulty is encountered in metastatic squamous cell carcinoma from other sites (eg, skin, cervix).
• Although TTF1 is sensitive for lung adenocarcinoma, it can rarely be positive in lung squamous cell carcinoma. In addition, primary neuroendocrine neoplasms are frequently TTF1-positive. All thyroid carcinomas express the marker except the anaplastic variant. In addition, it can be expressed in pancreatobiliary, gastrointestinal, breast, endometrial, ovarian, and urothelial carcinomas, though the staining is typically patchy and focal. 46, 48 • Napsin A shows low sensitivities in primary lung mucinous adenocarcinoma and sarcomatoid carcinoma. It can also be expressed in renal cell carcinoma, ovarian and endometrial clear cell carcinoma, and thyroid and adrenocortical carcinoma. 49, 50 • GATA3: although highly sensitive for urothelial and breast carcinoma, it is also expressed in salivary gland and skin tumors, as well as cervical squamous cell carcinoma, pancreatobiliary adenocarcinoma, chromophobe renal cell carcinoma, and mesothelioma. 15 Its sensitivity, however, is extremely low in lung neoplasms, hence its usefulness in lung-derived specimens. 46 
CONCLUSION
Ancillary studies can be useful in pulmonary cytologic specimens for refining a diagnosis, resolving a differential diagnosis, or for predictive purposes in primary lung carcinomas. Judicious use of ancillary studies is crucial for minimizing the loss of diagnostic material in these small specimens.
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